Skip to main content
. 2022 Jun 6;40(25):2878–2888. doi: 10.1200/JCO.22.00839

FIG 4.

FIG 4.

Deepness of response. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, and oxaliplatin; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, and irinotecan.